Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact... Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions

Oncology and Therapy , Volume 5 (1) – Jan 5, 2017

Loading next page...
 
/lp/springer-journals/patient-reported-outcomes-pros-as-part-of-value-based-care-can-shape-CL0t2GJd3y

References (33)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0038-7
Publisher site
See Article on Publisher Site

Abstract

Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact.

Journal

Oncology and TherapySpringer Journals

Published: Jan 5, 2017

There are no references for this article.